Efficacy of Pulsed Light Therapy for Meibomian Gland Dysfunction and Dry Eye Syndrome
Withdrawn before enrolling · Not applicable · Has a placebo group
Conditions studied: Meibomian Gland Dysfunction, Dry Eye Syndrome
In brief
Our primary aim is to determine whether pulsed light therapy (PLT) is effective in reducing symptoms and improving clinical stigmata of dry eye syndrome (DES) associated with meibomian gland dysfunction (MGD) in patients with facial rosacea (which includes ocular rosacea). The uses of PLT are for treatment of rosacea, hair removal, pigmented lesions, and skin telangiectasias. The risks include the potential for transient sunburn-like sensations (i.e. redness, burning sensation) and particularly if not used properly, the potential to cause burns, blistering, scarring, and pigmentary changes.
Key facts
- Study ID
- NCT01917539
- Run by
- University of Miami
- People needed
- 0
- Starts
- 2013-06-01
- Expected to finish
- 2015-05-01
- Last updated by the study team
- 2018-06-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age greater or equal to 18 y/o
- Patients presenting to academic referral center for DES
- Diagnosis of mild to moderate DES with meibomian gland dysfunction and ocular rosacea, based on evaluation of meibomian glands (MG), MG secretions, and other factors
- Facial rosacea
- Patients must not have started any new medications within the past 1 month
- Patients should not be using warm compresses or lid scrubs more than 1-2 times in the previous 2 weeks
- Symptomatic changes in DES
You may not qualify if…
- Age < 18
- History of inflammatory DES (e.g. Sjogren's, rheumatoid arthritis, Stevens-Johnson syndrome, ocular cicatricial pemphigoid)
- History of trauma-induced ocular surface disease (thermal burns, chemical burns)
- Severe DES
- Pregnant women
- H/o seizures
- Significant unprotected sun exposure or use of tanning beds or creams in treated area (must be discontinued at least 2 weeks prior to treatment, during treatment course, and 2 weeks after last treatment)
- Use of Accutane, anti-coagulants, or St. John's Wort
- Active infections/immunosuppression
- Herpes 1 or 2 within the treatment area
- Patients who have undergone LASIK surgery within the past 12 months
Where it is running
- University of Miami Bascom Palmer Eye Institute — Miami, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.